• Kura Oncology launched Caspian Therapeutics with USD 50 million financing to advance KO-7246, a menin inhibitor for diabetes.
• Preclinical results were selected for future oral presentation at EASD on Sept. 29, 2026.
• Animal and human islet studies showed improved insulin production and glycemic control, suggesting potential durable restoration of β-cell function.
• Funding targets IND-enabling work and initial clinical proof-of-concept, while Kura retains about half ownership on a fully diluted basis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED9823304) on September 09, 2026, and is solely responsible for the information contained therein.